Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints – MarketWatch

Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints – MarketWatch
Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints  MarketWatchShares of biotech Athenex, Inc. ATNX, +2.43% rose 3.8% in premarket trade Monday after the company announced that two Phase 3 studies of KX2-391, …
Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints – MarketWatch